PMID- 16382124
OWN - NLM
STAT- MEDLINE
DCOM- 20060209
LR  - 20071115
IS  - 1527-7755 (Electronic)
IS  - 0732-183X (Linking)
VI  - 24
IP  - 1
DP  - 2006 Jan 1
TI  - Comparable long-term survival after unrelated and HLA-matched sibling donor 
      hematopoietic stem cell transplantations for acute leukemia in children younger 
      than 18 months.
PG  - 145-51
AB  - PURPOSE: To describe outcomes after unrelated donor stem cell transplantation 
      (HCT) in children (< 18 months at diagnosis) with acute leukemia and compare 
      these with outcomes after human leukocyte antigen (HLA)-matched sibling donor 
      HCT. PATIENTS AND METHODS: We compared the results of unrelated donor HCT with 
      bone marrow (n = 85) or cord blood grafts (n = 81) and HLA-matched sibling donor 
      HCT with bone marrow grafts (n = 101) for acute myeloid or acute lymphoblastic 
      leukemia using Cox proportional hazards models. Unrelated donor HCT recipients 
      were younger, more likely to have MLL gene rearrangement, to have advanced 
      leukemia, and to receive irradiation before HCT. RESULTS: Treatment-related 
      mortality rates were 6%, 15%, and 31% after matched sibling, unrelated donor bone 
      marrow, and cord blood HCT, respectively. Risks of relapse, overall and 
      leukemia-free survival were significantly associated with disease status at 
      transplantation. Though leukemia recurrence was lowest after unrelated donor HCT 
      in first clinical remission (CR), overall survival, and leukemia-free survival 
      rates were similar after matched sibling and unrelated donor HCT, after 
      adjustment for disease status. Relapse, overall and leukemia-free survival did 
      not differ by graft type (bone marrow v cord blood) or type of leukemia. 
      Three-year probabilities of leukemia-free survival were 49% and 54% after 
      HLA-matched sibling and unrelated donor transplantation in first CR, 
      respectively. Corresponding rates for those with advanced leukemia were 20% and 
      30%. CONCLUSION: Unrelated donor HCT should be considered for infants with acute 
      leukemia in first CR using the same eligibility criteria as are currently used 
      for those with HLA matched sibling donors.
FAU - Eapen, Mary
AU  - Eapen M
AD  - Center for Blood and Marrow Transplant Research, Medical College of Wisconsin, 
      Milwaukee, WI 53226, USA. meapen@mail.mcw.edu
FAU - Rubinstein, Pablo
AU  - Rubinstein P
FAU - Zhang, Mei-Jie
AU  - Zhang MJ
FAU - Camitta, Bruce M
AU  - Camitta BM
FAU - Stevens, Cladd
AU  - Stevens C
FAU - Cairo, Mitchell S
AU  - Cairo MS
FAU - Davies, Stella M
AU  - Davies SM
FAU - Doyle, John J
AU  - Doyle JJ
FAU - Kurtzberg, Joanne
AU  - Kurtzberg J
FAU - Pulsipher, Michael A
AU  - Pulsipher MA
FAU - Ortega, Juan J
AU  - Ortega JJ
FAU - Scaradavou, Andromachi
AU  - Scaradavou A
FAU - Horowitz, Mary M
AU  - Horowitz MM
FAU - Wagner, John E
AU  - Wagner JE
LA  - eng
GR  - U24-CA76518/CA/NCI NIH HHS/United States
PT  - Comparative Study
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Clin Oncol
JT  - Journal of clinical oncology : official journal of the American Society of 
      Clinical Oncology
JID - 8309333
SB  - IM
MH  - Female
MH  - Graft vs Host Disease/epidemiology
MH  - *Hematopoietic Stem Cell Transplantation
MH  - *Histocompatibility Testing
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Leukemia, Myeloid, Acute/blood/mortality/*therapy
MH  - Male
MH  - Neutrophils/physiology
MH  - Platelet Count
MH  - Precursor Cell Lymphoblastic Leukemia-Lymphoma/blood/mortality/*therapy
MH  - Recurrence
MH  - Siblings
MH  - Survivors
EDAT- 2005/12/31 09:00
MHDA- 2006/02/10 09:00
CRDT- 2005/12/31 09:00
PHST- 2005/12/31 09:00 [pubmed]
PHST- 2006/02/10 09:00 [medline]
PHST- 2005/12/31 09:00 [entrez]
AID - 24/1/145 [pii]
AID - 10.1200/JCO.2005.02.4612 [doi]
PST - ppublish
SO  - J Clin Oncol. 2006 Jan 1;24(1):145-51. doi: 10.1200/JCO.2005.02.4612.